Half Yearly Report and Accounts
Released
Released
Announcement PDF
HALF YEAR
REPORT
ADALTA LIMITED AND CONTROLLED ENTITIES
ABN 92 120 332 925
FOR THE PERIOD ENDING
31 DECEMBER 2025
AdAlta Limited and controlled entities
Appendix 4D
Half-year report
1
1. Company details
Name of entity: AdAlta Limited
ABN: 92 120 332 925
Reporting period: For the half-year ended 31 December 2025
Previous period: For the half-year ended 31 December 2024
2. Results for announcement to the market
$
Revenues from ordinary activities down 18.4% to 306,150
Loss from ordinary activities after tax attributable to the owners of AdAlta
Limited down 5.4% to (2,437,141)
Loss for the half-year attributable to the owners of AdAlta Limited down 5.4% to (2,437,141)
Dividends
There were no dividends paid, recommended or declared during the current financial period.
Comments
The loss for the Group after providing for income tax amounted to $2,437,141 (31 December 2024: $2,576,431).
3. Net tangible assets
Reporting
period
Previous
period
Cents Cents
Net tangible assets per ordinary security (0.01) 0.02
4. Control gained over entities
Not applicable.
5. Loss of control over entities
Not applicable.
6. Dividends
Current period
There were no dividends paid, recommended or declared during the current financial period.
Previous period
There were no dividends paid, recommended or declared during the previous financial period.
7. Details of associates and joint venture entities
Not applicable.
AdAlta Limited and controlled entities
Appendix 4D
Half-year report
2
8. Foreign entities
Details of origin of accounting standards used in compiling the report:
Not applicable.
9. Audit qualification or review
Details of audit/review dispute or qualification (if any):
The financial statements were subject to a review by the auditors and the review report is attached as part of the Half year
financial report.
10. Attachments
Details of attachments (if any):
The Half year financial report of AdAlta Limited for the half-year ended 31 December 2025 is attached.
11. Signed
Signed ___________________________
Date: 19 February 2026
Paul MacLeman
Chairman
Melbourne
AdAlta Limited and controlled entities
Corporate directory
31 December 2025
3
Directors Dr Paul MacLeman
Dr Timothy Oldham
Dr David Fuller
Ms Michelle Burke
Company secretary Mr Cameron Jones
Registered office Level 1, Suite 1, 117 Camberwell Road
Hawthorn East, VIC 3123
Australia
Auditor Dry Kirkness (Audit) Pty Ltd
Ground Floor,
50 Colin Street
West Perth, Western Australia 6005
Share Registry Automic Registry Services
Level 5
126 Phillip Street
Sydney, NSW 2000
Tel: 1300 288 664
Stock exchange listing AdAlta Limited shares are listed on the Australian Securities Exchange Ltd.
ASX Code 1AD and listed options under ASX:1ADO
Website www.adalta.com.au
4
5
9
10
12
14
15
16
AdAlta Limited and controlled entities
Contents
31 December 2025
Directors' report
Auditor's independence declaration
Independent Auditors Review Report to the Members of AdAlta Limited
Directors' declaration
Consolidated statement of profit or loss and other comprehensive income
Consolidated statement of financial position
Consolidated statement of changes in equity
Consolidated statement of cash flows
Notes to the consolidated financial statements
13
17
AdAlta Limited and controlled entities
Directors' report
31 December 2025
5
The Directors of AdAlta Limited ("AdAlta" or "the Group") present their report, together with the financial statements, of the
Group for the half-year ended 31 December 2025.
Directors
The following persons were Directors of the Group during the whole of the financial half-year and up to the date of this report,
unless otherwise stated:
Dr Paul MacLeman Non-Executive Chairman
Dr Timothy Oldham Chief Executive Officer and Managing Director
Dr David Fuller Non-Executive Director
Ms Michelle Burke Non-Executive Director
Review of operations
1. Company strategy, principal activities and purpose
AdAlta is a clinical stage biotechnology company focused on the discovery and development of next generation cell and
protein-based therapeutics. Its uses its translational and early clinical development platform, capital efficient operating model
and third party program financing to add value to, and monetise early clinical stage assets. Current programs address the
need for effective cellular immunotherapies for the treatment of solid cancers, the need for more effective therapies for fibrotic
diseases such as Idiopathic Pulmonary Fibrosis (“IPF”) and the opportunity to transform malaria prophylaxis.
Through its 'East to West' cellular immunotherapy strategy, the Company’s subsidiary, AdCella Pty Ltd, is integrating Asia's
prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to
create a pathway connecting 'Eastern' innovation in cellular immunotherapies with 'Western' regulated markets and patients.
AdCella in-licenses clinical stage T cell immunotherapies, establishes manufacturing and completes initial US FDA compliant
clinical trials in Australia, then on-licenses to larger biopharmaceutical companies, sharing the value created with AdCella’s
in-licensing partners. This strategy is the key growth driver for AdAlta.
AdAlta has previously developed assets using its proprietary i-body® technology for which it is now seeking partnerships to
crystallise the value that previous R&D investment has created. AD-214, a phase II ready, first in class i-body-fusion protein,
takes a whole new approach to fibrotic diseases of the lung (such as IPF) and kidney. WD-34 is a discovery stage i-body®
that AdAlta believes is the first antibody-like molecule showing both high potency against malaria parasite invasion and activity
against multiple strains of malaria.
The Company aims to convert this value to revenue by out-licensing product candidates after Phase 1 clinical trials to larger
biopharmaceutical companies in return for upfront payments, development and commercialisation milestone payments,
royalties and in some cases equity in partner companies. In the case of cell therapy programs, revenue is shared with in-
licensing partners. The primary focus of the H1 FY26 period was to formally launch AdCella's 'East to West' cellular
immunotherapy operations through execution of a major collaboration to co-develop a groundbreaking Chimeric Antigen
Receptor-T cell (“CAR-T”) therapy for mesothelioma and other solid cancers, strengthen the Company's balance sheet, and
advance partnering opportunities for AD-214 and WD-34.
2. Key H1 FY26 results
'East to West' cellular immunotherapy operations launched
● Executed a Development and Collaboration Agreement with Shanghai Cell Therapy Group Co Ltd ('SHcell') to co-develop
BZDS1901, a first-in-class PD1 armoured MSLN CAR-T for mesothelioma and other solid cancers (announced 2 January
2026)
- BZDS1901 has demonstrated complete responses in difficult to treat advanced mesothelioma patients with overall
response rates substantially in excess of current standard of care
- BZDS1901 is armoured to overcome tumour immune suppression and features rapid (<2 day), low-cost, non-viral vector
manufacturing process, positioning it well for scalability
- AdCella made first milestone payment of US$1.0 million (~A$1.5 million) to SHcell
● New US FDA manufacturing requirements align with AdCella's manufacturing scalability and automation strategy
AdAlta Limited and controlled entities
Directors' report
31 December 2025
6
Financing
● Raised $2.8 million via placements including $1.6 million at market pricing during the December 2025 quarter and $1.2
million post period end in January 2026 at a 67% higher price.
● Received $0.93 million R&D Tax Incentive (“RDTI”) refund in respect of FY25, including $0.78 million during the period
and $0.15 million received post period end following a favourable first Advance Overseas Finding for offshore CAR-T
development expenses
● Improved balance sheet:
- Repaid Radium RDTI advance loan facility in full
- Completed obligations under NLSC and Meurs Group investment agreements; remaining NLSC subscription amount
repaid in cash; no further shares to be issued under these agreements
● Reduced quarterly cash operating costs by 31% (Q2 FY26 vs Q1 FY26) reflecting continued cost management initiatives
3. AdCella: 'East to West' cellular immunotherapies
Cellular immunotherapies are living drugs that involve engineering a patient's own immune cells to find and fight cancer. These
highly specialised products offer potential cures for cancer in a single or limited number of doses. AdAlta's 'East to West'
strategy seeks to bring the transformative outcomes that cellular immunotherapies have brought to blood cancers to patients
with solid tumours which represent 90% of all cancers.
AdAlta’s subsidiary, AdCella, sources clinically validated cellular immunotherapies developed in Asia (approximately 40% of
all companies and 60% of all clinical trials are located in Asia), and co-develops these assets through Western (US FDA)
regulatory pathways using Australian clinical trial and manufacturing infrastructure. The model is designed to:
● Reduce early-stage discovery risk;
● Shorten development timelines;
● Materially lower development capital intensity; and
● improve probability of successful commercialisation and strategic transaction outcomes.
AdCella acts as a force multiplier, creating value for larger biopharmaceutical companies by 'Westernising' these innovative
assets and generating confirmatory clinical data, with this value shared with in-licensing partners. This platform-based
structure enables AdCella to scale a multi-asset pipeline while preserving capital efficiency and minimising balance sheet risk.
Co-development of BZDS1901 with Shanghai Cell Therapy Group launches AdCella operations
AdCella operations were officially launched at the end of the period (announced 2 January 2026) by entering a Development
and Collaboration Agreement with Shanghai Cell Therapy Group Co Ltd ('SHcell') to co-develop BZDS1901, a next-
generation, armoured CAR-T therapy targeting mesothelin (MSLN), for markets outside greater China.
BZDS1901 is a highly differentiated, first in class, CAR-T therapy incorporating an anti-PD1 armouring mechanism designed
to overcome tumour immune suppression within the solid tumour microenvironment. The therapy has demonstrated
meaningful clinical responses, including complete responses, in investigator-initiated clinical studies in patients with advanced
and refractory solid tumours, including mesothelioma.
Key features of BZDS1901 include
● A well established target: MSLN is highly expressed in mesothelioma (35,000+ new cases and 29,000+ deaths
annually, forecast market of $12.2 billion by 2034) and other solid cancers including lung, ovarian and pancreatic cancers.
● Armoured design: BZDS1901 secretes a PD1 blocker (checkpoint inhibitor) to prevent tumours from shutting down
immune responses, a first-in-class approach that could make it far more effective in solid tumours.
● Clinical promise: An early version demonstrated 63.5% overall response rate (vs 11-29% for current standard of care)
with 25-26 month median survival (vs 8-9 months for standard of care) in advanced mesothelioma patients. The current
version, still undergoing dose optimisation, has achieved response rates double that achieved with standard of care just
10% of the dose of the earlier version, including multiple complete responses which is a significant achievement in this
patient population. These early studies have also enabled optimisation of protocols to manage and improve the safety of
BZDS1901.
● Scalable manufacturing: Produced in under two days using proprietary non-viral technology at substantially lower cost,
compared to 9-10 days for most CAR-T therapies.
AdAlta Limited and controlled entities
Directors' report
31 December 2025
7
Under the Agreement, AdCella receives an exclusive license to develop and commercialize BZDS1901 outside greater China.
AdCella will establish manufacturing, secure a US FDA IND and conduct a Phase 1 clinical trial in up to 18 patients. The total
development budget to end of Phase 1 is US$14-19 million over four years inclusive of milestone payments to SHcell. AdCella
will acquire a 60% share of proceeds from any commercialization event. AdCella is financing development via third party
investors, with AdAlta expected to retain majority ownership after initial financing. In addition to its founding shareholding,
AdAlta has invested US$1.0 million in AdCella to finance initial milestone payments to SHcell and will provide management
services to AdCella on an ongoing basis.
FDA regulatory developments support AdCella strategy
On 11 January 2026, the US FDA announced increased flexibility on manufacturing requirements for cell and gene therapies,
reducing quality burdens, employing more adaptable product specification expectations and streamlining process validation.
This will reduce the cost and time to transition from Phase 1 to Phase 2 studies and enable more extensive process
improvement, enhancing the commercial viability of AdCella's pipeline.
4. i-body® enabled assets
AD-214 – fibrotic diseases: AD-214 is a first in class, next generation protein therapeutic for fibrotic diseases including lung
fibrosis (for example IPF) and kidney fibrosis. Using AdAlta's proprietary i-body® technology to target the receptor CXCR4,
AD-214 has been shown to be well tolerated in Phase 1 clinical studies and effective in multiple animal models of disease,
with patent protection beyond 2036.
The Company is working to out-license AD-214 to regional and global biopharmaceutical companies for both lung and kidney
indications to finance Phase 2 trials. The majority of recent enquiries have focused on kidney fibrosis applications, reflecting
the growing focus on diabetes and metabolic diseases. Interest in fibrosis assets remains significant, with several new
enquiries received during the period.
Of particular note, the US FDA approved Boehringer Ingelheim's Jascayd for IPF in October 2025, the first new therapeutic
option for IPF patients in over a decade. Despite this new option, there is still no cure for IPF and the opportunity for additional
new products such as AD-214 targeting new modes of action remains significant.
WD-34 – malaria: WD-34 is an i-body® discovered with La Trobe University that targets a highly conserved region of the
AMA1 protein crucial for malaria parasite invasion. WD-34 recognises AMA1 from multiple malaria species as well as Babesia
and Toxoplasma parasites. This pan-strain recognition combined with high potency inhibition suggests potential for a long
acting, single dose prophylaxis for travellers and deployed personnel, seasonal prophylaxis for children in endemic regions or
a novel method of antigen generation for vaccines.
La Trobe University and other interested parties are working with AdAlta to finance additional candidate optimisation and pre-
clinical proof of concept studies for WD-34. Grant applications are progressing and discussions to form a new company (similar
to AdCella) to attract equity investment are advancing.
5. Future milestones
Near term (6-9 month) milestones include
● 'East to West' cellular immunotherapies
- Securing additional financing via direct third party investment into AdCella
- Completing a pre-IND meeting with FDA to confirm the BZDS1901 technology transfer program and the content of the
IND submission
- Treating a further 2-7 patients with BZDS1901 under an ongoing IIT in China
- Commencing remaining non-clinical IND-enabling studies
- Securing an Australian contract manufacturing organisation and commencing technology transfer of BZDS1901
- Advancing discussions to in-license a second product for AdCella's pipeline
● AD-214 and WD-34:
- The Company continues to maintain and renew a pipeline of active discussions with parties interested in licensing or
co-investing in AD-214 and WD-34. For competitive and practical reasons, AdAlta is unable to forecast when, or even if,
specific partnership agreements and the transactions that flow from them may close.
AdAlta Limited and controlled entities
Directors' report
31 December 2025
8
Financial results
The loss for the Group after providing for income tax amounted to $2,437,141 (31 December 2024: $2,576,431).
The half-year ended 31 December 2025 operating results included the following:
● Research and development expenditure of $1,607,550 (31 December 2024: $495,350);
● Corporate and administration expenses of $632,039 (31 December 2024: $1,484,400);
● Share based payment expense of $18,328 (31 December 2024: $45,356); and
● Net foreign exchange loss of $1,252 (31 December 2024: $7,773)
During the period the Group received the Research and Development Tax Incentive (RDTI) cash refund of $781,841 for the
2024/2025 financial year (31 December 2024: $1,774,530) and repaid in full the outstanding $0.47 million balance of the
Radium Capital R&D Tax Incentive Loan Advance Facility. Also during the period the Group adopted a range of cost saving
measures to preserve cash. These included continued suspension of Board and Managing Director fees and salary. The
Board is evaluating a combination of ad hoc payments and equity remuneration in lieu of foregone and/or delayed
remuneration and the appropriate time to implement these.
The cash position as at 31 December 2025 was $1,583,394 (31 December 2024: $1,627,036 and 30 June 2025: $1,305,594).
Corporate developments
The Company’s 2025 Annual General Meeting was held on 26 November 2025. All resolutions were passed, including
approval of the remuneration report, re-election of Michelle Burke as a Director, approval of share issuances, renewal of
Omnibus Equity plan and approval of 10% placement capacity under ASX listing rule 7.1A. All resolutions were carried with
support of more than 98% of shares voted.
Matters subsequent to the end of the financial half-year
On 2 January 2026, the Company announced the execution of the Development and Collaboration Agreement with SHcell to
co-develop BZDS1901 (as described in section 3 above).
On 13 January 2026, the Company announced it had received firm commitments to raise $1.2 million before costs at $0.005
per share, representing a 67% premium to the October 2025 placements. The placement was facilitated by 62 Capital Pty Ltd
who are entitled to a fee of 6% of the gross proceeds raised, to be settled in shares and options on the same terms as the
placement plus 75 million Lead Manager Options. 254.4 million new fully paid ordinary shares and 202.2 million new
ASX:1ADO listed options were issued on settlement of the placement.
Post period end, and in accordance with the terms of the BZDS1901 Development and Collaboration Agreement with SHcell,
AdCella has made two payments of US$0.5 million (~A$1.5 million in total) to SHcell. The payments were made using funds
invested by AdAlta Ltd in return for an anticipated increased share of AdCella post the first external financing.
An additional $0.15 million Research and Development Tax Incentive refund was received in January 2026 following a
favourable Advance Overseas Finding in respect of certain offshore research expenses for CAR-T cell therapy products in
the Company's 'East to West' cellular immunotherapy pipeline.
No other matter or circumstance has arisen since 31 December 2025 that has significantly affected, or may significantly affect
the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out
immediately after this Directors' report.
This report is made in accordance with a resolution of Directors, pursuant to section 306(3)(a) of the Corporations Act 2001.
On behalf of the Directors
___________________________
Paul MacLeman
Chairman
19 February 2026
AUDITOR’S INDEPENDENCE DECLARATION
As lead auditor for the review of AdAlta Limited for the half year ended 31 December 2025, I declare that,
to the best of my knowledge and belief, there have been:
a) No contraventions of the auditor independence requirements of the Corporations Act 2001 in
relation to the review; and
b) No contraventions of any applicable code of professional conduct in relation to the review.
This declaration is in respect of AdAlta Limited and the entities it controlled during the period.
DRY KIRKNESS (AUDIT) PTY LTD
LUCY P GARDNER
Director
Perth
Date: 19 February 2026
INDEPENDENT AUDITOR’S REVIEW REPORT
TO THE MEMBERS OF ADALTA LIMITED
Conclusion
We have reviewed the accompanying half year financial report of AdAlta Limited (“the Company”)
and its controlled entities (“the Group”), which comprises the consolidated statement of financial
position as at 31 December 2025 and the consolidated statement of profit or loss and other
comprehensive income, consolidated statement of changes in equity and consolidated statement of
cash flows for the half year ended on that date, a summary of material accounting policy information
and the directors’ declaration.
Based on our review, which is not an audit, nothing has come to our attention that causes us to
believe that the accompanying half year financial report of the Group is not in accordance with the
Corporations Act 2001 including:
a) giving a true and fair view of the Group’s financial position as at 31 December 2025 and of its
financial performance for the half year ended on that date; and
b) complying with Accounting Standard AASB 134 Interim Financial Reporting and the
Corporations Regulations 2001.
Basis for Conclusion
We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410
Review of a Financial Report Performed by the Independent Auditor of the Entity. Our responsibilities are
further described in the Auditor’s responsibilities for the review of the half year financial report section of
our report.
We are independent of the Group in accordance with the auditor independence requirements of the
Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical
Standards Board’s APES 110 Code of Ethics for Professional Accountants (including Independence
Standards) (the Code) that are relevant to our audit of the annual financial report in Australia. We have
also fulfilled our ethical requirements in accordance with the Code.
Material Uncertainty Related to Going Concern
We draw attention to Note 2 in the half year financial report, which indicates that the Group had a
net liability position of $218,656 as at 31 Dec 2025, incurred a loss after tax of $2,437.141 and had
net cash outflows from operating activities of $489,869 for the half-year ended 31 December 2025.
As stated in Note 2, these conditions, along with other matters as set forth in Note 2, indicate that a
material uncertainty exists that may cast significant doubt on the Group’s ability to continue as a
going concern. Our conclusion is not modified in respect of this matter.
Directors’ responsibilities for the half year financial report
The directors of the Company are responsible for the preparation and fair presentation of the half year
financial report in accordance with the Accounting Standard AASB 134 Interim Financial Reporting and
the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable
the preparation of the half year financial report that gives a true and fair view and is free from material
misstatement, whether due to fraud or error.
Auditor’s responsibilities for the half year financial report
Our responsibility is to express a conclusion on the half year financial report based on our review. ASRE
2410 requires us to conclude whether we have become aware of any matter that makes us believe that
the half year financial report has not been prepared, in all material respects, in accordance with the
Corporations Act 2001 including; giving a true and fair view of the Group’s financial position as at 31
December 2025 and its financial performance and its cash flows for the half year ended on that date;
and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations
Regulations 2001
A review of a half year financial report consists of making enquiries, primarily of persons responsible for
financial and accounting matters, and applying analytical and other review procedures. A review is
substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and
consequently does not enable us to obtain assurance that we would become aware of all significant
matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
DRY KIRKNESS (AUDIT) PTY LTD
LUCY P GARDNER
Director
Perth
Date: 19 February 2026
AdAlta Limited and controlled entities
Directors' declaration
31 December 2025
12
In the Directors' opinion:
● the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard
AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting
requirements;
● the attached financial statements and notes give a true and fair view of the company's financial position as at 31
December 2025 and of its performance for the financial half-year ended on that date; and
● there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and
payable.
Signed in accordance with a resolution of Directors made pursuant to section 303(5)(a) of the Corporations Act 2001.
On behalf of the Directors
___________________________
Paul MacLeman
Chairman
19 February 2026
AdAlta Limited and controlled entities
Consolidated statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2025
Note 31 Dec 2025 31 Dec 2024
$ $
The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the
accompanying notes
13
Revenue 4 306,150 375,086
Expenses
Corporate administration expenses (external) (632,039) (1,484,400)
Corporate and administration (Employee benefit expenses) (96,222) (327,321)
Depreciation and amortisation expense - (70,570)
Finance costs (247,412) (29,420)
Net foreign exchange (loss) / gain (1,252) (7,773)
Patent and legal costs (99,250) (99,396)
Research and development expenses 5 (1,607,550) (495,350)
Research and development expenses (Employee benefit expenses) (41,238) (391,931)
Share based payment expenses (18,328) (45,356)
Total expenses (2,743,291) (2,951,517)
Loss before income tax expense (2,437,141) (2,576,431)
Income tax expense - -
Loss after income tax expense for the half-year attributable to the owners of
AdAlta Limited (2,437,141) (2,576,431)
Other comprehensive income for the half-year, net of tax - -
Total comprehensive income for the half-year attributable to the owners of
AdAlta Limited (2,437,141) (2,576,431)
Cents Cents
Basic earnings per share 7 (0.16) (0.42)
Diluted earnings per share 7 (0.16) (0.42)
AdAlta Limited and controlled entities
Consolidated statement of financial position
As at 31 December 2025
Note 31 Dec 2025 30 Jun 2025
$ $
The above consolidated statement of financial position should be read in conjunction with the accompanying notes
14
Assets
Current assets
Cash and cash equivalents 1,583,394 1,305,594
Trade and other receivables and prepayments 265,499 835,969
Total current assets 1,848,893 2,141,563
Total assets 1,848,893 2,141,563
Liabilities
Current liabilities
Trade and other payables 6 1,962,414 821,668
Borrowings 8 - 446,785
Provisions 105,135 68,276
Total current liabilities 2,067,549 1,336,729
Non-current liabilities
Provisions - 27,184
Financial liabilities - 1,375,894
Total non-current liabilities - 1,403,078
Total liabilities 2,067,549 2,739,807
Net liabilities (218,656) (598,244)
Equity
Issued capital 9 51,974,224 49,197,823
Reserves 10 2,266,766 2,226,438
Accumulated losses (54,459,646) (52,022,505)
Total deficiency in equity (218,656) (598,244)
AdAlta Limited and controlled entities
Consolidated statement of changes in equity
For the half-year ended 31 December 2025
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes
15
Issued Retained
Total equity
capital Reserves profits
$ $ $ $
Balance at 1 July 2024 47,399,255 2,151,428 (47,520,237) 2,030,446
Loss after income tax expense for the half-year - - (2,576,431) (2,576,431)
Other comprehensive income for the half-year, net of tax - - - -
Total comprehensive income for the half-year - - (2,576,431) (2,576,431)
Transactions with owners in their capacity as owners:
Share-based payments - 45,356 - 45,356
Issue of ordinary shares on conversion of investment
agreement 600,000 - - 600,000
Balance at 31 December 2024 47,999,255 2,196,784 (50,096,668) 99,371
Issued Retained Total
deficiency in
equity
capital Reserves profits
$ $ $ $
Balance at 1 July 2025 49,197,823 2,226,438 (52,022,505) (598,244)
Loss after income tax expense for the half-year - - (2,437,141) (2,437,141)
Other comprehensive income for the half-year, net of tax - - - -
Total comprehensive income for the half-year - - (2,437,141) (2,437,141)
Transactions with owners in their capacity as owners:
Share-based payments - 18,328 - 18,328
Issue of ordinary shares on conversion of investment
agreement 1,201,000 - - 1,201,000
Share issue costs (97,439) 22,000 - (75,439)
Issue of ordinary shares 1,666,000 - - 1,666,000
Settlement of unpaid shares 6,840 - - 6,840
Balance at 31 December 2025 51,974,224 2,266,766 (54,459,646) (218,656)
AdAlta Limited and controlled entities
Consolidated statement of cash flows
For the half-year ended 31 December 2025
31 Dec 2025 31 Dec 2024
$ $
The above consolidated statement of cash flows should be read in co
Share your feedback
Discover